AusBiotech members unite in response to R&D Tax Incentive review

7 February 2020

More than 100 members have attended AusBiotech consultation meetings this week or made submissions, as the industry organization prepares its response in the government’s window for comment on the Review of the Research & Development (R&D) Tax Incentive.

AusBiotech briefings, held in Sydney, Brisbane and Melbourne with the support of Deloitte, were held to inform members and seek contributions to the crafting of the industry’s response to the ‘Ferris, Finkel, Fraser’ Review of the R&D Tax Incentive. The federal government has invited feedback on the Report’s six recommendations, until October 28, 2016.

Strong themes in response to the report’s package of recommendations include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK